<DOC>
	<DOCNO>NCT00913627</DOCNO>
	<brief_summary>The purpose study assess efficacy safety single dose ibuprofen 600 mg extend release formulation post-operative dental pain . There concern manufacturing process may affect performance characteristic select prototype . Therefore , two formulation prototype manufacture two different process , [ roller compaction ] [ wet granulation ] include study . The preferred prototype manufacture two different method compare placebo . This study also characterize pharmacokinetic/pharmacodynamic relationship formulation .</brief_summary>
	<brief_title>Study Evaluating Ibuprofen 600 mg Extended Release ( ER ) For Dental Pain</brief_title>
	<detailed_description />
	<mesh_term>Toothache</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>INCLUSION CRITERIA : Males females 16 40 year age . Outpatients undergo surgical extraction 12 third molar , one must partial full bony mandibular impaction moderate severe postoperative pain ( confirm VAS score least 50 mm 100 mm VAS ) follow surgical extraction ; Use follow preoperative medication ( ) /anesthetic ( ) : shortacting local anesthetic ( mepivacaine lidocaine ) without vasoconstrictor , nitrous oxide , and/or midazolam ; Reliable , cooperative , adequate intelligence record request information analgesic questionnaire form ; Examined attend dentist physician medically clear participate study ; In general good health contraindication study medication . EXCLUSION CRITERIA : Pregnancy , verify urinebased pregnancy test , breast feeding ; Presence serious medical condition ( e.g. , poorly control hypertension , poorly control diabetes , significantly impaired cardiac , renal hepatic function , poorlycontrolled hyper hypothyroidism ) ; Use prescription nonprescription drug administration ibuprofen NSAID contraindicate ; Use bisphosphonate ( e.g. , risedronate [ Actonel ] , alendronate [ Fosamax ] , ibandronate [ Boniva ] ) past 5years ; Acute localize dentalveolar infection time surgery could confound postsurgical evaluation ; Females childbearing potential , postmenopausal less 2 year use medically approve method contraception ( i.e. , oral , transdermal , implanted contraceptive , intrauterine device , diaphragm , condom , abstinence , surgical sterility ) , females test positive urinebased pregnancy test ; Presence history ( within 2 year enrollment ) bleed disorder ( ) peptic ulcer disease ; History alcoholism ( i.e. , average , consume 3 alcoholic drink per day ) substance abuse within last year , currently abuse alcohol moodaltering drug ( e.g. , cannabis ) . Patients take CNS psychotropic drug ( include St. John 's Wort , nutritional supplement know psychotropic effect ) may enrol stable dos medication least 2 month , maintain dose throughout study , condition judge Principal Investigator wellcontrolled ; Habituation analgesic drug ( i.e. , routine use oral analgesic 5 time per week ) History allergic reaction ( e.g. , asthma , rhinitis , swell , shock , hive ) ibuprofen , naproxen , aspirin , NSAID ; codeine , hydrocodone , acetaminophen , combination ; Prior use type analgesic NSAID five halflives drug less take first dose study medication , except preanesthetic medication anesthesia procedure ; Ingestion caffeinecontaining beverage , chocolate , alcohol 4 hour less take first dose study medication ; The subject take investigational product participate investigational trial within 30 day study enrollment ; The subject previously participate study ; The subject member study site staff directly involve study , employee Sponsor , relative study site personnel directly involve study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Extended-release , ibuprofen</keyword>
</DOC>